SCHEMBL24166124

SCHEMBL24166124

COCCn1cnc2ccc(N)c(-c3cccnc3OC)c2c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
HSD17B10 Q99714 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
GAA P10253 2/20 0.37
GLA P06280 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 1/20 0.36
KCNA3 P22001 1/20 0.36
BRAF P15056 1/20 0.35
HRH4 Q9H3N8 1/20 0.35
MAPT P10636 2/20 0.35
ATM Q13315 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
BTK Q06187 1/20 0.35
MAPK1 P28482 1/20 0.35
MTOR P42345 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30656810 1.00 KMT2A (0.38) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL24166135 0.83 GAA (0.41) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL30656847 0.83 GAA (0.41) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL30656856 0.82 KMT2A (0.40) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL24166155 0.82 KMT2A (0.40) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL24166503 0.81 ALDH1A1 (0.43) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL30656811 0.81 ALDH1A1 (0.43) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL24166121 0.80 CLK1 (0.43) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL30656848 0.80 CLK1 (0.43) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL24166480 0.79 ALOX15 (0.46) KMT2AHSD17B10ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC KMT2A 3393/4885HSD17B10 271/4885KDM4E 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.